Trial Profile
Long-term study of HP-3060 in patients with perennial allergic rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Emedastine (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions
- Sponsors Hisamitsu Pharmaceutical
- 10 May 2017 Status changed from recruiting to completed.
- 08 Jun 2016 New trial record